Results 91 to 100 of about 2,758 (199)

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of Two-Year Efficacy and Safety Outcomes in Two Phase 3 Trials [PDF]

Rationale & Objective: Atypical hemolytic uremic syndrome (aHUS) is a rare form of thrombotic microangiopathy (TMA) caused by complement dysregulation. Ravulizumab is a complement C5 inhibitor (C5i) approved for the treatment of aHUS.
Adams B, Amancha P, Aris ADM, Cataland S, Chakravarty S, Dixon BP, Garlo K, Greenbaum LA, Heyne N, Kang HG, Kavanagh D, Kim SH, Luque Y, Miyakawa Y, Muff-Luett M, Ogawa M, Tanaka L, Wang E, Yoon S   +18 more
core  

Ravulizumab as an alternative for gemcitabine related trombotic microangiopathy: A case report

Nefrología (English Edition)
Thrombotic microangiopathy (TMA) is characterized by endotelial damage, microangiopathic hemolytic anemia, thrombocytopenia and organ damage, particularly renal. In Oncology, TMA can be secondary to the cancer itself or related to oncological treatments.
Cristina Riaza Ortiz, Marta Calvo Arévalo, Marta Álvarez Nadal, Antonio Casado, Ana I. Sánchez-Fructuoso, Clara García-Carro   +5 more
doaj   +1 more source

The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark:Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment [PDF]

Objectives: To establish epidemiology, healthcare costs, and labor market attachment in patients with paroxysmal nocturnal hemoglobinuria (Pt-PNH) in Denmark.
Frederiksen, Henrik, Olsen, Jens, Pedersen, Mikkel, Rich, Carly, Wilson, Koo   +4 more
core   +1 more source

Ravulizumab for adults with generalized myasthenia gravis: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Generalized myasthenia gravis (often shortened to gMG) is a rare health condition that causes muscular weakness. This summary gives an overview of three published articles that report the results of research studies of a ...
Florencia Aguirre, Renata Andrade
doaj   +1 more source

SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor [PDF]

, 2021
Barcellini W., Cecchi N., Fattizzo B., Giannotta J. A.   +3 more
core   +1 more source

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network

Frontiers in Immunology
ObjectiveTo integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors ...
Luqiong Wang, Jiaojiao Chen, Huixiang Li, Lin Wang, Feiyu Liu, Xiaoli Jiang   +5 more
doaj   +1 more source

Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial

Thrombosis Journal
Background Atypical hemolytic uremic syndrome (aHUS) is a rare disease with poor outcomes when untreated, in which ravulizumab or eculizumab are the standard of care where available.
Masanori Matsumoto, Akihiko Shimono, Jun Yokosawa, Keiichiro Hirose, Edward Wang, Shoichi Maruyama   +5 more
doaj   +1 more source

Real-World Case Series of Ravulizumab Use in Patients with Myasthenia Gravis in Romania

Brain Sciences
Background and Objectives: Ravulizumab, a long-acting C5 complement inhibitor, was approved in the US and Europe in 2022 as an add-on therapy for the standard treatment of AChR-positive generalized MG (gMG).
Crisanda Vîlciu, Oana Antonia Mihalache, Bogdan Marius Istrate, Mihaela Aftinia Marian, Mirela Ramona Drăghici, Diana Mihaela Petrescu, Adriana Octaviana Dulămea, Daniela Cristina Anghel   +7 more
doaj   +1 more source

Ravulizumab

Reactions Weekly, 2022
openaire   +2 more sources

Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ©)

Patient Preference and Adherence, 2020
Karen Kaiser,1 Susan E Yount,1 Christa E Martens,1 Kimberly A Webster,1 Sara Shaunfield,1 Amy Sparling,1 John Devin Peipert,1 David Cella,1 Scott T Rottinghaus,2 Bonnie MK Donato,2 Richard Wells,3 Ioannis Tomazos2 1Department of Medical Social Sciences ...
Kaiser K, Yount SE, Martens CE, Webster KA, Shaunfield S, Sparling A, Peipert JD, Cella D, Rottinghaus ST, Donato BMK, Wells R, Tomazos I   +11 more
doaj